Evolus, Inc. (FRA:EVL)

Market Cap	314.85M
Revenue (ttm)	243.61M
Net Income (ttm)	-49.91M
Shares Out	n/a
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	280
Open	5.10
Previous Close	5.10
Day's Range	5.10 - 5.10
52-Week Range	5.00 - 14.20
Beta	n/a
RSI	30.77
Earnings Date	Mar 6, 2026

About Evolus

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 332
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EVL

Financial Performance

In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.

Financial numbers in USD